Browsing tag:

159351-69-6


Novartis gains FDA approval for Afinitor in advanced breast cancer marking a significant milestone for women battling this disease. Everolimus CAS# 159351-69-6, is the active ingredient for Afinitor®. Click for more information on, and availability of Everolimus. Also, click for more articles on breast cancer and the HER2 receptor. The approval was based on a[…]

Read More

The Oncology segment of the pharmaceutical industry is not only a fast growing one, but it is also an area where shortages are anticipated. A decrease in availability of sterile injectable oncology drugs have been reported since 2007.  Furthermore, many of the sterile injectable oncology drugs that experienced shortages in 2010 and 2011 had a[…]

Read More

In 2009 a new anti-cancer drug, Everolimus, was approved in the US and Europe specifically for use in patients with advanced kidney cancer who were unresponsive to the standard chemotherapy regimen. As a kinase inhibitor, Everolimus effectively inhibits cancer cells from dividing. Since then, the use of Everolimus has extended to treatment of subependymal giant[…]

Read More

For organ transplant patients, the normally protective immune response can threaten the longevity and function of the transplanted organ. Currently, organ transplant patients must take immunosuppressive or anti-rejection medication to prevent the immune system from fighting against the new, transplanted organ. Often a choice is made between the certain damage of a steroid drug, and[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service